<DOC>
	<DOCNO>NCT00997477</DOCNO>
	<brief_summary>This study evaluate correct use sequential formoterol budesonide inhaler capsule treatment via Aerolizer patient satisfaction adult asthmatic .</brief_summary>
	<brief_title>Correct Use Sequential Formoterol Budesonide Inhaler Capsule Treatment Via Aerolizer Patient Satisfaction Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Moderate persistent asthmatic patient . No previous Aerolizer experience . Lifethreatening asthma : A subject must lifethreatening asthma history significant asthma episode ( ) require intubation associate hypercapnia , respiratory arrest hypoxic seizure , asthmarelated syncopal episode ( ) . Worsening asthma : A subject must experience worsen asthma involve hospitalization within 6 month screen , emergency room visit three time past 6 month , use oral corticosteroid worsen asthma within 3 month screen . Unstable asthma : During screen period , patient require use &gt; 8 puffs/day salbutamol 100 mcg per actuation pMDI two consecutive day . A subject must upper respiratory tract infection within 4 week screen . FEV1 &lt; 60 % screening . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>aerolizer</keyword>
	<keyword>formoterol</keyword>
	<keyword>budesonide</keyword>
	<keyword>asthma</keyword>
</DOC>